Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3228161 | 0.97 | CYP1A2 (0.56) | CYP1A2TDP1HTR1APHGDHMGLL | |
| Hydrochloric Acid SCHEMBL7438943 | 0.97 | CYP1A2 (0.56) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL14534799 | 0.91 | HTT (0.55) | CYP1A2TDP1HTR1AHTTPOLB | |
| Methylpiperazine SCHEMBL11736744 | 0.87 | CYP1A2 (0.46) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL422638 | 0.85 | — | — | |
| SCHEMBL572569 | 0.85 | ALDH1A1 (0.45) | CYP1A2TDP1HTR1AHTTPOLB | |
| Carbamic Acid SCHEMBL29922252 | 0.79 | CYP1A2 (0.52) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| Acetamide SCHEMBL4743096 | 0.79 | CYP1A2 (0.60) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL2133787 | 0.79 | CYP1A2 (0.54) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL31706681 | 0.79 | CYP1A2 (0.46) | CYP1A2TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619106-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | Neupharma, Inc (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | claimed |
| CN-117510413-A | DCLK1 kinase inhibitor and preparation method and application thereof | 杭州医学院 | 2024-02-06 | — | — | CN | claimed |
| US-20230265083-A1 | Heterocycle CDK Inhibitors And Their Use Thereof | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-24 | — | — | US | claimed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | claimed |
| CN-116283920-A | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2023-06-23 | — | — | CN | claimed |
| CN-116239580-A | Triazine compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2023-06-09 | — | — | CN | claimed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | claimed |
| WO-2023056441-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | claimed |
| EP-1024407-A1 | POSITIVE PHOTOSENSITIVE POLYIMIDE COMPOSITION | PI R & D Co Ltd (JP) | 2000-08-02 | — | — | EP | claimed |
| WO-1999058549-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
| EP-0710293-A1 | LYOPHILIZED LIGAND-RECEPTOR COMPLEXES FOR ASSAYS AND SENSORS | U.S. DRUG TESTING, INC. (US) | 1996-05-08 | — | — | EP | claimed |
| WO-1995002703-A1 | LYOPHILIZED LIGAND-RECEPTOR COMPLEXES FOR ASSAYS AND SENSORS | U.S. DRUG TESTING, INC. (US) | 1995-01-26 | — | — | WO | claimed |
| WO-1994024095-A1 | IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | claimed |
| US-5354654-A | Lyophilized ligand-receptor complexes for assays and sensors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1994-10-11 | — | — | US | claimed |
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | claimed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | claimed |
| US-3981868-A | MICROBIOCIDES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CYP1A2 2671/4885TDP1 321/4885HTR1A 3126/4885 |
| US-20230265083-A1 | Heterocycle CDK Inhibitors And Their Use Thereof | CDK3, CDK8, CDK9 | CYP1A2 1943/4885TDP1 367/4885HTR1A 3236/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CYP1A2 2671/4885TDP1 321/4885HTR1A 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.